Boehringer Ingelheim International GmbH;Zealand Pharma A/S
发明人:
Ditte Riber,Jakob Lind Tolborg,Dieter Wolfgang Hamprecht
申请号：
US14516216
公开号：
US09988429B2
申请日:
2014.10.16
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
